Stellenbosch-based biotechnology start-up Immobazyme has successfully closed its latest funding round, bringing its total investment to R24.5-million. The new injection of capital will enable the company to double the size of its facility and scale up production capabilities, positioning itself at the forefront of South Africa’s biotechnology industry.
Founded in 2019, Immobazyme has experienced year-on-year growth, culminating in the opening of its state-of-the-art independent laboratory last year. This infrastructure milestone, supported by the doubling of its research team, has advanced the company’s goal of providing sustainable and affordable biologics to the global market.
